Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27 | Direct | 70,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
1 source rowRow 1 · 2023-11-08 · Other · Disposed 618,894 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $266.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 332 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $266.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 5,401 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $161.16 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 1,044 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $161.16 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 31,506 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $94.29 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 635 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $94.29 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 29,865 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $107.18 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 1,207 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $107.18 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 38,793 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 207 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $58.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 45,293 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-11-08 · Disposition to issuer · Disposed 889 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $110.80 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-11-08 · Disposition to issuer · Disposed 12,811 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $99.66 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-11-08 · Disposition to issuer · Disposed 17,700 · Balance 0 F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2017 Filed Oct 4, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,532 | $58.87 | $90,188.84 |
DisclosureSEC source: 0001144204-17-051413 · v476460_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,752 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 21:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1,434 | $121.78 | $174,632.52 |
DisclosureSEC source: 0001144204-17-035811 · v470322_form4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,284 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 40,000 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · derivative · entry 7 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,039 Underlying: Common Stock · 40,000 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 2,043 | $133.07 | $271,872.02 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · nonDerivative · entry 6 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,718 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. F7 · price: This transaction was executed in multiple trades at prices ranging from $132.945 to $133.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 5,485 | $132.54 | $726,995.61 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · nonDerivative · entry 5 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 573,761 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. F6 · price: This transaction was executed in multiple trades at prices ranging from $131.93 to $132.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 5,893 | $131.18 | $773,049.63 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · nonDerivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,246 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $130.925 to $131.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 18,763 | $130.46 | $2,447,845.37 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,139 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $129.92 to $130.92. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 7,816 | $129.49 | $1,012,100.87 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603,902 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $128.89 to $129.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 26, 2017 Filed Jun 28, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 40,000 | $8.67 | $346,668.00 |
DisclosureSEC source: 0001144204-17-034719 · v469875_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 611,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 20, 2017. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 1.187 | $115.00 | $136.50 |
DisclosureSEC source: 0001144204-17-019294 · v463645_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,718 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOptions to Purchase Common Stock · Derivative | 40,000 | $0.00 Strike: $107.18 | $0.00 |
DisclosureSEC source: 0001144204-17-006031 · v458364_4.xml · derivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-02-01 F2 · derivative.exercise_date: 25% of the shares of common stock underlying this option will vest on January 1, 2018, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 23,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-006031 · v458364_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,905 F1 · shares: 25% of the shares of restricted stock will vest on January 1, 2018, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2021 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 2,802 | $103.92 | $291,181.32 |
DisclosureSEC source: 0001144204-17-000939 · v456334_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,705 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| December 23, 2016 Filed Feb 14, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-009175 · v459550_5.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 572,905 F1 · kind: The reporting person made a gift to a 501(c)(3) charitable foundation. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 2,405 | $0.00 Strike: $31.90 | $0.00 |
DisclosureSEC source: 0001144204-16-138636 · v454690_4.xml · derivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354 Underlying: Common Stock · 2,405 shares Expires 2023-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The remainder of the shares originally underlying this option vest on a pro rata monthly basis through January 1, 2017, subject to the terms and conditions the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 1,082 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001144204-16-138636 · v454690_4.xml · derivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,082 shares Expires 2022-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 2,405 | $31.90 | $76,719.50 |
DisclosureSEC source: 0001144204-16-138636 · v454690_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 1,082 | $21.50 | $23,263.00 |
DisclosureSEC source: 0001144204-16-138636 · v454690_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 553,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 21:07 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 705 | $163.20 | $115,055.79 |
DisclosureSEC source: 0001144204-16-127099 · v450071_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,020 F1 · kind: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 8,411 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001144204-16-124959 · v449286_4.xml · derivative · entry 5 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,411 shares Expires 2018-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionOptions to Purchase Common Stock · Derivative | 26,589 | $0.00 Strike: $8.67 | $0.00 |
DisclosureSEC source: 0001144204-16-124959 · v449286_4.xml · derivative · entry 4 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,039 Underlying: Common Stock · 26,589 shares Expires 2020-08-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. F2 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | SaleCommon Stock | 35,000 | $165.00 | $5,775,000.00 |
DisclosureSEC source: 0001144204-16-124959 · v449286_4.xml · nonDerivative · entry 3 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,725 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 8,411 | $9.82 | $82,615.37 |
DisclosureSEC source: 0001144204-16-124959 · v449286_4.xml · nonDerivative · entry 2 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
| September 20, 2016 Filed Sep 22, 2016 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Exercise / conversionCommon Stock | 26,589 | $8.67 | $230,438.89 |
DisclosureSEC source: 0001144204-16-124959 · v449286_4.xml · nonDerivative · entry 1 Pruzanski Mark · CIK 0001559569 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 579,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.